Advanced Discovery Platform Abterra leverages next-generation sequencing, mass spectrometry, and machine learning to map antibody responses and provide access to a broad antibody repertoire, enabling partners to accelerate discovery of novel therapeutics.

NF1 Target Expertise The company has partnered to develop high-affinity antibody reagents for NF1 detection across western blot, ELISA, and immunohistochemistry, highlighting strength in challenging targets and cross-assay validation—appealing to NF1-focused programs.

Product Offerings Alicanto antibody discovery service is part of Abterra's catalog, offering a ready-to-run discovery workflow that can be scaled to client timelines, providing a boxed option for partners seeking rapid, proven discovery capabilities.

Regional Growth Recent expansion plans and office moves signal capability to support customers across West Coast and Southeast regions, enabling faster on-site collaboration, pilots, and local program management.

Small Team Agility With a lean team and strong academic roots in bioinformatics, Abterra can offer flexible engagement models, rapid iteration, and customized discovery programs tailored to early-stage biotech and academic partnerships.